

Dispense as written/Brand medically necessary

Referral Status:	MRN:	
New referral	Order change	Order Renewal
Patient preferred clinic:		

Substitution permitted

чH	,								New referral	Orde	· chan	ge	0	rder Ren	ewal	
	INFUSIO ne: 1-800-809-1265			_Q-	72_802	20		Patient	preferred clinic:							
	iris <sup>®</sup> (eculizuma						of Treatme	nt foi	· Paroxysmal	Noctu	rnal	Hemo	glob	inuri	а	
PATI	ENT DEMOGRAPHI	ICS:														
Date of Referral:							Patient's Phone:									
Patie	nt Name:							Address:								
Date	of Birth:							City, State, Zip:								
Heigh	t in inches:	We	eight:		LB	or	KG	Gender: Allergies:					:	See list	Ν	IKDA
DIAG	NOSIS: (PLEASE CO	DM	PLETE 2	ND	AND 3	RD	DIGITS TO COI	MPLET	E ICD 10 FOR BIL	LING)						
	D59.5 - Paroxysmal No									•						
	Other:															
	UESTED DOCUMEN	ITA'	TION:						ON: HAS THIS PATIE	NT TAKE	N THI	S MEDICA	TION	BEFOR	?	
1	Insurance information		16 11 111				NO: IF YES:									
2	History & Physical/Tried	d and	d failed the	era		PLEASE STATE REQUIRED WASHOUT		LAST INFUSION DATE:								
3 4	Full medication list REQUIRED: Document	atio	n of monin	100		FROM PREVIOUS THERAPY:	NEXT INFUSION DATE:  IF ORDER CHANGE:									
4	vaccine (MenACWY AN			_			IF UKI	TER CHANGE:								
	weeks prior to start of th	nera	ру					Continue cu	ırrent o	rder	until ins	uran	ce ap	orov	ed	
MED	ICATION ORDERS:															
	Patient may be ineligible to	rece	eive eculizun	nab	if receivi	ing a	antibiotics for active in	nfectious	process, antifungal therag	py, active fe	ver an	ıd/or suspect	ed infed	ction, pres	sents v	vith any
sympto	ms of meningococcal infecti	ions,	and/or surg	gery	<i>l</i> .							· '		, ,		,
	EDICATION TO BE ADMINI Labeling does not sugge							I AS SELE	ECTED							
	Diphenhydramine		25mg		i0mg				Acetaminophen	325n	ng	500mg	6	50mg	1	000mg
13.7	Methylprednisolone		40mg	1	25mg		Other:		Famotidine	20m	3	40mg				
IV	Famotidine		20mg	4	0 mg				Diphenhydramine	25m	)	50mg				
	Other:							РО	Fexofenadine	60m	3	180mg				
MED	ICATION:								Cetirizine	10mg	3					
<b>✓</b>	Soliris <sup>®</sup> (eculizumab)	) IV	given ove	er (	35 minเ	utes	s diluted in NS		Loratadine	10m	3					
	according to FDA lab								Other:							
If t	he infusion is slowe	•				tim	e should not									
	e	xce	ed 2 hou	ırs	<b>5.</b>			SPEC	IAL/OTHER LAB C	RDERS:						
*	Follow each infusion w	vith	a 1 hour	pos	st infus	ion	monitoring*		<u></u>							
FDF/	NITNOV/DOCE.															
FREC	QUENCY/DOSE: Induction: 600mg IV	' aiv	en weekl	lv f	or 1 we	مماده	3									
	Maintenance (to beg	-		-				na IV ai	ven once every 2 w	ıeeks						
	Other:	0	WOOK O	, 11	10001111	<u>g .</u>	<u> </u>	9 1 9	von oneo overy 2 w	CONO						
		ribe	r must be	en	rolled i	in th	ne Soliris (REMS)	progra	ım, at 1 888 765 4747	7 or at wy	/w.sc	olirisrems.c	com.			
							` ,		Refills x 12 months					e:		
LINIE	USE/CARE ORDERS	c.														
LINE	Start PIV/Access CV							ADVERSE REACTION & ANAPHYLAXIS ORDERS:  Administer acute infusion and anaphylaxis								
			etandard	flu	ishina r	nro	cedure	medications per Palmetto Infusion standing								
Flush device per facility standard flushing procedure							adverse reaction orders, which can be found at									
									our website or scan l	nere				•		
PRES	SCRIBER INFORMAT	ΓΙΟ	N:													
PROVIDER NAME:								PHONE:								
ADDRESS:								FAX:								
CITY, STATE, ZIP:								NPI:								
	SCRIBER SIGNATUR	E: (	No <u>stan</u>	gn	signat	tur	es)						DAT	E:		